



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



BMS 195614

Item No. 16029

CAS Registry No.: 182135-66-6
Formal Name: 4-[[[5,6-dihydro-5,5-dimethyl-8-(3-quinolinyl)-2-naphthalenyl]carbonyl]amino]-benzoic acid
Synonym: BMS 614
MF: C₂₉H₂₄N₂O₃
FW: 448.5
Purity: ≥98%
UV/Vis.: λ_{max}: 211, 236, 282 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BMS 195614 is supplied as a crystalline solid. A stock solution may be made by dissolving the BMS 195614 in the solvent of choice, which should be purged with an inert gas. BMS 195614 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of BMS 195614 in these solvents is approximately 30 mg/ml.

BMS 195614 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BMS 195614 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. BMS 195614 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BMS 195614 is a neutral retinoic acid receptor (RAR) α -selective antagonist ($K_i = 2.5$ nM).¹ It antagonizes agonist-induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear receptor corepressor binding.²

References

1. Géhin, M., Vivat, V., Wurtz, J.-M., *et al.* Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. *Chem. Biol.* **6**(8), 519-529 (1999).
2. Germain, P., Gaudon, C., Pogenberg, V., *et al.* Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. *Chem. Biol.* **16**(5), 479-489 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/16/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM